Dominiek M.
- Country
- Belgium
- Department
- Haematology
Research Overview
- Safety and Tolerability of REGN17235 in Adults with Clonal Cytopenia of Undetermined Significance or Low‑Risk SF3B1‑Mutated Myelodysplastic Syndrome
- First-in-Human, Open-Label Study of INCA035784 in Adults with Myeloproliferative Neoplasms
- Evaluation of Venetoclax and Azacitidine Combination Therapy Versus Placebo and Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome
Data & Insights
Has run more than one trial at 146 of 283 partner sites.
Specializations
Myeloid Disorders
The investigator demonstrates significant expertise in treating myeloproliferative neoplasms and related conditions, with particular focus on myelofibrosis and its various presentations.
- JAK inhibitor-naïve myelofibrosis
- Advanced systemic mastocytosis
- Chronic myeloid leukemia
- Polycythemia vera
Their work encompasses both treatment-naïve patients and those with refractory conditions.
Myelodysplastic Syndromes
The investigator specializes in treating higher-risk myelodysplastic syndrome, exploring various therapeutic combinations and innovative treatment approaches.
- RARA-positive myelodysplastic syndrome
- Newly diagnosed higher-risk MDS
- Treatment-naïve MDS populations
Their research focuses on novel therapeutic combinations including targeted agents and standard treatments.
Therapeutic Approaches
The investigator explores multiple therapeutic modalities across hematologic conditions, incorporating both established and experimental treatments.
- Selective inhibitor therapies
- Combination treatment strategies
- Novel molecular targeted agents
- Monotherapy applications
Their work includes evaluation of various therapeutic combinations for optimal patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.